STOCK TITAN

[Form 4] Iridex Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 08/27/2025. The filing shows three open-market acquisitions totaling 1,000 shares: 500 shares at $1.28, 250 shares at $1.2746, and 250 shares at $1.2964. Each line reports the resulting beneficial ownership rising sequentially to 50,245; 50,495; and 50,745 shares, and ownership is reported as direct. No derivative transactions were reported. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.

Romeo R. Dizon, Chief Financial Officer di IRIDEX Corp (IRIX), ha dichiarato acquisti di azioni ordinarie in data 27/08/2025. La comunicazione riporta tre acquisizioni sul mercato aperto per un totale di 1.000 azioni: 500 azioni a $1,28, 250 azioni a $1,2746 e 250 azioni a $1,2964. Ciascuna riga indica un aumento progressivo della partecipazione beneficiaria a 50.245; 50.495; e 50.745 azioni, e la detenzione è riportata come diretta. Non sono state segnalate transazioni su strumenti derivati. Il Modulo 4 è firmato da un procuratore per conto della persona che effettua la segnalazione.

Romeo R. Dizon, Director Financiero (CFO) de IRIDEX Corp (IRIX), informó compras de acciones ordinarias el 27/08/2025. El documento muestra tres adquisiciones en mercado abierto que suman 1.000 acciones: 500 acciones a $1.28, 250 acciones a $1.2746 y 250 acciones a $1.2964. Cada línea refleja el aumento secuencial de la participación beneficiaria a 50.245; 50.495; y 50.745 acciones, y la titularidad se informa como directa. No se registraron operaciones con derivados. El Formulario 4 está firmado por un apoderado en nombre de la persona informante.

IRIDEX Corp (IRIX)의 최고재무책임자(CFO) Romeo R. Dizon이 2025년 8월 27일 보통주 매수를 보고했습니다. 제출서류에는 장외거래가 아닌 공개시장 매수 세 건으로 총 1,000주가 기재되어 있습니다: 500주를 $1.28에, 250주를 $1.2746에, 250주를 $1.2964에 매수했습니다. 각 항목은 수혜적 보유가 순차적으로 50,245주, 50,495주, 50,745주로 증가했음을 보고하며, 보유 형태는 직접으로 기재되어 있습니다. 파생상품 거래는 보고되지 않았습니다. Form 4에는 보고인을 대신한 대리인의 서명이 포함되어 있습니다.

Romeo R. Dizon, directeur financier (CFO) d'IRIDEX Corp (IRIX), a déclaré des achats d'actions ordinaires le 27/08/2025. Le dépôt fait état de trois acquisitions sur le marché ouvert totalisant 1 000 actions : 500 actions à 1,28 $, 250 actions à 1,2746 $ et 250 actions à 1,2964 $. Chaque ligne indique que la détention bénéficiaire augmente successivement à 50 245 ; 50 495 ; et 50 745 actions, et la détention est déclarée directe. Aucune transaction sur dérivés n'a été signalée. Le formulaire 4 est signé par un mandataire au nom de la personne déclarante.

Romeo R. Dizon, Chief Financial Officer von IRIDEX Corp (IRIX), meldete am 27.08.2025 Käufe von Stammaktien. Die Meldung weist drei Erwerbe am offenen Markt mit insgesamt 1.000 Aktien aus: 500 Aktien zu $1,28, 250 Aktien zu $1,2746 und 250 Aktien zu $1,2964. In jeder Zeile steigt das wirtschaftliche Eigentum nacheinander auf 50.245; 50.495; und 50.745 Aktien an, und das Eigentum wird als direkt angegeben. Es wurden keine Derivatgeschäfte gemeldet. Das Formular 4 ist von einem Bevollmächtigten im Namen der meldenden Person unterschrieben.

Positive
  • Transparent disclosure of three open-market purchases with exact share counts and prices
  • Direct ownership reported, ending at 50,745 shares, clarifying insider stake
  • No derivatives reported, simplifying assessment of insider exposure
Negative
  • None.

Insights

TL;DR: Insider purchased 1,000 IRIX shares in small separate trades, increasing direct holdings to 50,745 shares.

The reported transactions are routine open-market purchases by the company's CFO totaling 1,000 shares executed on 08/27/2025 at prices between $1.2746 and $1.2964. The filing lists incremental beneficial ownership amounts after each trade, ending at 50,745 shares held directly. There are no derivative instruments disclosed and no amendments noted. From a financial analysis perspective, these are small, transparent purchases recorded under Section 16 reporting rules and provide limited new information about company operations or financial performance.

TL;DR: Form 4 properly discloses direct insider purchases and is signed by an authorized attorney-in-fact.

The Form 4 identifies the reporting person, relationship as Chief Financial Officer, and discloses three purchase transactions on 08/27/2025 with exact share counts and prices, satisfying disclosure requirements. Ownership is explicitly listed as direct. The signature block shows the form was executed by an attorney-in-fact, which is permitted when properly authorized. There are no indications of Rule 10b5-1 plan use or derivative activity. Compliance-wise, the filing appears complete for the disclosed transactions.

Romeo R. Dizon, Chief Financial Officer di IRIDEX Corp (IRIX), ha dichiarato acquisti di azioni ordinarie in data 27/08/2025. La comunicazione riporta tre acquisizioni sul mercato aperto per un totale di 1.000 azioni: 500 azioni a $1,28, 250 azioni a $1,2746 e 250 azioni a $1,2964. Ciascuna riga indica un aumento progressivo della partecipazione beneficiaria a 50.245; 50.495; e 50.745 azioni, e la detenzione è riportata come diretta. Non sono state segnalate transazioni su strumenti derivati. Il Modulo 4 è firmato da un procuratore per conto della persona che effettua la segnalazione.

Romeo R. Dizon, Director Financiero (CFO) de IRIDEX Corp (IRIX), informó compras de acciones ordinarias el 27/08/2025. El documento muestra tres adquisiciones en mercado abierto que suman 1.000 acciones: 500 acciones a $1.28, 250 acciones a $1.2746 y 250 acciones a $1.2964. Cada línea refleja el aumento secuencial de la participación beneficiaria a 50.245; 50.495; y 50.745 acciones, y la titularidad se informa como directa. No se registraron operaciones con derivados. El Formulario 4 está firmado por un apoderado en nombre de la persona informante.

IRIDEX Corp (IRIX)의 최고재무책임자(CFO) Romeo R. Dizon이 2025년 8월 27일 보통주 매수를 보고했습니다. 제출서류에는 장외거래가 아닌 공개시장 매수 세 건으로 총 1,000주가 기재되어 있습니다: 500주를 $1.28에, 250주를 $1.2746에, 250주를 $1.2964에 매수했습니다. 각 항목은 수혜적 보유가 순차적으로 50,245주, 50,495주, 50,745주로 증가했음을 보고하며, 보유 형태는 직접으로 기재되어 있습니다. 파생상품 거래는 보고되지 않았습니다. Form 4에는 보고인을 대신한 대리인의 서명이 포함되어 있습니다.

Romeo R. Dizon, directeur financier (CFO) d'IRIDEX Corp (IRIX), a déclaré des achats d'actions ordinaires le 27/08/2025. Le dépôt fait état de trois acquisitions sur le marché ouvert totalisant 1 000 actions : 500 actions à 1,28 $, 250 actions à 1,2746 $ et 250 actions à 1,2964 $. Chaque ligne indique que la détention bénéficiaire augmente successivement à 50 245 ; 50 495 ; et 50 745 actions, et la détention est déclarée directe. Aucune transaction sur dérivés n'a été signalée. Le formulaire 4 est signé par un mandataire au nom de la personne déclarante.

Romeo R. Dizon, Chief Financial Officer von IRIDEX Corp (IRIX), meldete am 27.08.2025 Käufe von Stammaktien. Die Meldung weist drei Erwerbe am offenen Markt mit insgesamt 1.000 Aktien aus: 500 Aktien zu $1,28, 250 Aktien zu $1,2746 und 250 Aktien zu $1,2964. In jeder Zeile steigt das wirtschaftliche Eigentum nacheinander auf 50.245; 50.495; und 50.745 Aktien an, und das Eigentum wird als direkt angegeben. Es wurden keine Derivatgeschäfte gemeldet. Das Formular 4 ist von einem Bevollmächtigten im Namen der meldenden Person unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/27/2025 P 500 A $1.28 50,245 D
Common Stock 08/27/2025 P 250 A $1.2746 50,495 D
Common Stock 08/27/2025 P 250 A $1.2964 50,745 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 08/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What trades did IRIX CFO Romeo R. Dizon report on Form 4?

He reported three purchases on 08/27/2025 totaling 1,000 shares: 500 at $1.28, 250 at $1.2746, and 250 at $1.2964.

What was Romeo Dizon's beneficial ownership after these transactions?

The filing shows sequential beneficial ownership amounts of 50,245, 50,495, and 50,745 shares following each reported purchase.

Were any derivative securities reported by the insider in this Form 4?

No. Table II for derivative securities contains no reported transactions.

Who signed the Form 4 for Romeo R. Dizon?

The Form 4 was signed by Nilo De Castro, Attorney-in-fact on behalf of Romeo R. Dizon on 08/28/2025.

Do the transactions indicate use of a 10b5-1 trading plan?

The filing does not indicate that the trades were made pursuant to a Rule 10b5-1 plan; no box or instruction identifying such a plan is checked in the provided content.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

22.09M
12.24M
27.64%
15.83%
1.68%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW